Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 Next >
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
From AstraZeneca
Via Business Wire
Tickers AZN
ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
From AstraZeneca
Via Business Wire
Tickers AZN
Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
From AstraZeneca
Via Business Wire
Tickers AZN
ULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
From AstraZeneca
Via Business Wire
Tickers AZN
EVUSHELD™  significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees
From AstraZeneca
Via Business Wire
Tickers AZN
EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies
From AstraZeneca
Via Business Wire
Tickers AZN
LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
From AstraZeneca
Via Business Wire
Tickers AZN
Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU
From AstraZeneca
Via Business Wire
Tickers AZN
TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma
From AstraZeneca
Via Business Wire
Tickers AZN
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
From AstraZeneca
Via Business Wire
Tickers AZN
TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma
From AstraZeneca
Via Business Wire
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study
From AstraZeneca
Via Business Wire
Tickers AZN
CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care
From AstraZeneca
Via Business Wire
Tickers AZN
LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.